期刊
PLOS ONE
卷 16, 期 2, 页码 -出版社
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0237480
关键词
-
资金
- Austrian Science Promotion Agency (FFG) [880687]
- German Research Council [GRK 2504]
- Interdisciplinary Center for Clinical Research (IZKF) at the University hospital of the University of Erlangen-Nurnberg
- Marinomed Biotech AG
Iota-carrageenan has shown to inhibit cell entry of SARS-CoV-2 virus and replication, with potential antiviral effects demonstrated in vitro. Clinical studies have also indicated that iota-carrageenan can reduce severity and duration of symptoms caused by various respiratory viruses, suggesting it may be an effective prophylaxis or treatment for SARS-CoV-2 infections.
In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains a significant public health threat. Attachment and entry of coronaviruses including SARS-CoV-2 is mainly mediated by the spike glycoprotein. Here, we show that iota-carrageenan can inhibit the cell entry of the SARS-CoV-2 spike pseudotyped lentivirus in a dose dependent manner. SARS-CoV-2 spike pseudotyped lentivirus particles were efficiently neutralized with an IC50 value of 2.6 mu g/ml iota-carrageenan. Experiments with patient isolated wild type SARS-CoV-2 virus showed an inhibition of replication in a similar range. In vitro data on iota-carrageenan against various Rhino- and endemic Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction of severity and duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our in vitro data on SARS-CoV-2 spike pseudotyped lentivirus and replication competent SARS-CoV-2 suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据